Lisata Therapeutics Statistics
Share Statistics
Lisata Therapeutics has 8.39M shares outstanding. The number of shares has increased by -86.25% in one year.
| Shares Outstanding | 8.39M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.15% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 6.92M |
| Failed to Deliver (FTD) Shares | 37 |
| FTD / Avg. Volume | 0.23% |
Short Selling Information
The latest short interest is 17.06K, so 0.2% of the outstanding shares have been sold short.
| Short Interest | 17.06K |
| Short % of Shares Out | 0.2% |
| Short % of Float | 0.25% |
| Short Ratio (days to cover) | 1.79 |
Valuation Ratios
The PE ratio is -1.06 and the forward PE ratio is -1.15.
| PE Ratio | -1.06 |
| Forward PE | -1.15 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.46 |
| P/FCF Ratio | -1.1 |
| PEG Ratio | n/a |
Enterprise Valuation
Lisata Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 8.18, with a Debt / Equity ratio of 0.
| Current Ratio | 8.18 |
| Quick Ratio | 8.18 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.43% and return on capital (ROIC) is -47.97%.
| Return on Equity (ROE) | -0.43% |
| Return on Assets (ROA) | -0.38% |
| Return on Capital (ROIC) | -47.97% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -833.60K |
| Employee Count | 25 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -2.33M |
| Effective Tax Rate | 0.1 |
Stock Price Statistics
The stock price has increased by -5.84% in the last 52 weeks. The beta is 1.22, so Lisata Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.22 |
| 52-Week Price Change | -5.84% |
| 50-Day Moving Average | 2.86 |
| 200-Day Moving Average | 3.04 |
| Relative Strength Index (RSI) | 40.17 |
| Average Volume (20 Days) | 16.00K |
Income Statement
In the last 12 months, Lisata Therapeutics had revenue of $0 and earned -$20.84M in profits. Earnings per share was $-2.58.
| Revenue | 0 |
| Gross Profit | -189.00K |
| Operating Income | -25.71M |
| Net Income | -20.84M |
| EBITDA | -25.52M |
| EBIT | - |
| Earnings Per Share (EPS) | -2.58 |
Balance Sheet
The company has $22.59M in cash and $305.00K in debt, giving a net cash position of $22.29M.
| Cash & Cash Equivalents | 22.59M |
| Total Debt | 305.00K |
| Net Cash | 22.29M |
| Retained Earnings | -528.08M |
| Total Assets | 38.20M |
| Working Capital | 33.00M |
Cash Flow
In the last 12 months, operating cash flow was -$20.03M and capital expenditures $0, giving a free cash flow of -$20.03M.
| Operating Cash Flow | -20.03M |
| Capital Expenditures | 0 |
| Free Cash Flow | -20.03M |
| FCF Per Share | -2.48 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
LSTA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -100% |
| FCF Yield | -92.49% |
Analyst Forecast
The average price target for LSTA is $15, which is 481.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $15 |
| Price Target Difference | 481.4% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Sep 15, 2022. It was a backward split with a ratio of 1:15.
| Last Split Date | Sep 15, 2022 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -18.14 |
| Piotroski F-Score | 1 |